Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-23-014802
Filing Date
2023-04-26
Accepted
2023-04-26 16:10:30
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A pstx_defa14a_2023.htm DEFA14A 25153
2 GRAPHIC img123732084_0.jpg GRAPHIC 626656
3 GRAPHIC img123732084_1.jpg GRAPHIC 171544
  Complete submission text file 0000950170-23-014802.txt   1125580
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

EIN.: 472846548 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39376 | Film No.: 23849819
SIC: 2836 Biological Products, (No Diagnostic Substances)